Clinical Trials Logo

Exudative Macular Degeneration clinical trials

View clinical trials related to Exudative Macular Degeneration.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05093374 Recruiting - Clinical trials for Exudative Macular Degeneration

Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting

Start date: March 1, 2021
Phase: Phase 4
Study type: Interventional

The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and healthcare system (scheduling visits/treatments).

NCT ID: NCT04504123 Recruiting - Clinical trials for Wet Age-related Macular Degeneration

MMP-9 Inhibition for Recalcitrant Wet AMD

Start date: November 4, 2020
Phase: Phase 2
Study type: Interventional

Wet (or neovascular) form of age-related macular degeneration (wAMD) is the most common cause of blindness in the Western world. Currently, anti-vascular endothelial growth factor (VEGF) intravitreal injections (IVI) remain the standard-of-care treatment for wAMD. Previous studies show that about 90% of treated patients lose minimal visual function after 2 years of follow-up. There is still, a subset of 15% patients, incomplete responders, that do not improve and possibly worsen due to the persistence of sub-retinal fluid (with or without intra-retinal fluid) with chronic treatment. The investigators plan to evaluate the effect of oral doxycycline versus placebo on the anatomic and functional outcomes in persistent sub-retinal eye fluid in neovascular wet age-related macular degeneration. This subset are incomplete or non-responders to current anti-VEGF intravitreal therapy.